Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo

During the 2018–2020 Ebola virus disease outbreak in Democratic Republic of the Congo, a phase 3 trial of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine (DRC-EB-001) commenced in Goma, with participants being offered the two-dose regimen given 56 days apart. Suspension of trial activities in 2020 due to...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Vaccines Ročník 12; číslo 8; s. 828
Hlavní autoři:	Choi, Edward Man-Lik, Kasonia, Kambale, Kavunga-Membo, Hugo, Mukadi-Bamuleka, Daniel, Soumah, Aboubacar, Mossoko, Zephyrin, Edwards, Tansy, Tetsa-Tata, Darius, Makarimi, Rockyath, Toure, Oumar, Mambula, Grace, Brindle, Hannah, Camacho, Anton, Connor, Nicholas E., Mukadi, Pierre, McLean, Chelsea, Keshinro, Babajide, Gaddah, Auguste, Robinson, Cynthia, Luhn, Kerstin, Foster, Julie, Roberts, Chrissy h., Johnson, John Emery, Imbault, Nathalie, Bausch, Daniel G., Grais, Rebecca F., Watson-Jones, Deborah, Muyembe-Tamfum, Jean Jacques
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland MDPI AG 23.07.2024 MDPI
Témata:	Adenoviruses Adolescents Adults Age groups Antibodies Children Consortia COVID-19 COVID-19 vaccines Democratic Republic of the Congo DRC Ebola Ebola virus Ebolavirus Enzyme-linked immunosorbent assay Epidemics Glycoproteins Hypothesis testing Immunization Immunogenicity Immunoglobulin G Laboratories Medicine outbreak Pandemics Public health R Sample size Teenagers vaccine Vaccines Viral diseases Viruses Ankara Turkey Turkey Belgium Congo-Democratic Republic of Congo United States > US San Juan Capistrano California vaccine DRC Mvabea Zabdeno Ad26.ZEBOV MVA-BN-Filo outbreak interval Democratic Republic of the Congo Ebola immunogenicity
ISSN:	2076-393X, 2076-393X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!